biostudies-literatureUnknown131(11)Rossillon LSociété Française de Lutte Contre les Cancers et les Leucémies de l'Enfant et de l'AdolescentInstitut National Du CancerFondation Gustave RoussySociété Française de Lutte Contre les Cancers et les Leucémies de l&apos;Enfant et de l&apos;Adolescent<h4>Background</h4>Maintenance treatment with vinorelbine and oral cyclophosphamide (oral-CPM) improves outcome of nonmetastatic high-risk (HR) and very-high risk (VHR) rhabdomyosarcoma (RMS) patients. However, gonadal toxicity of maintenance was not yet investigated.<h4>Methods</h4>The authors focused their analysis on male gonadal toxicity in HR/VHR groups of RMS2005 trial, in France. In the HR group, patients were randomized to receive or not receive 6 months of maintenance (after nine or four IVADo] + five IVA). In the VHR group, patients received 6 months of maintenance (after four IVADo + five IVA). Exocrine gonadal dysfunction (EGD) was defined as followed: follicle-stimulating hormone level >10 IU/L and/or inhibin-B <80 pg/mL and/or oligoasthenozoospermia/azoospermia.<h4>Results</hCancere35918https://www.ebi.ac.uk/biostudies/studies/S-EPMC12117600biostudies-literatureImpact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France.PMC12117600Sarnacki SBolle SFresneau BDefachelles ASLenez LBarraud-Lange VOrbach DRossillon LTabone MDRome APlantaz DMinard-Colin VThomas-Teinturier CMetayer LBertrand ABernier-Chastagner VAnsoborlo SHaouy SPhilippe-Chomette PGuerin FAllodji RfalseImpact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France.<h4>Background</h4>Maintenance treatment with vinorelbine and oral cyclophosphamide (oral-CPM) improves outcome of nonmetastatic high-risk (HR) and very-high risk (VHR) rhabdomyosarcoma (RMS) patients. However, gonadal toxicity of maintenance was not yet investigated.<h4>Methods</h4>The authors focused their analysis on male gonadal toxicity in HR/VHR groups of RMS2005 trial, in France. In the HR group, patients were randomized to receive or not receive 6 months of maintenance (after nine or four IVADo] + five IVA). In the VHR group, patients received 6 months of maintenance (after four IVADo + five IVA). Exocrine gonadal dysfunction (EGD) was defined as followed: follicle-stimulating hormone level >10 IU/L and/or inhibin-B <80 pg/mL and/or oligoasthenozoospermia/azoospermia.<h4>Results</h2025-01-01T00:00:00Z2025 Jun2026-06-02T20:17:06.133Z2026-04-20T03:10:02.166ZS-EPMC121176004043387110.1002/cncr.35918